Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15109209 | 0.92 | ALDH1A1 (0.46) | HRH4HRH3ACHEMAPTERN1 | |
| SCHEMBL3676772 | 0.90 | TGM2 (0.46) | ACHEERN1TGM2TSHR | |
| SCHEMBL13055388 | 0.87 | MAPT (0.42) | HRH4HRH3ACHEMAPTCACNA1B | |
| SCHEMBL15809690 | 0.86 | ACHE (0.46) | HRH4HRH3ACHEERN1TGM2 | |
| SCHEMBL4678545 | 0.86 | ACHE (0.41) | HRH4HRH3ACHEMAPTCACNA1B | |
| SCHEMBL14458909 | 0.85 | ERN1 (0.41) | HRH4HRH3ACHEERN1ALDH1A1 | |
| SCHEMBL9547242 | 0.85 | ERN1 (0.40) | HRH4HRH3ACHEMAPTCACNA1B | |
| SCHEMBL23225642 | 0.85 | ACHE (0.48) | HRH4HRH3ACHEALDH1A1LMNA | |
| SCHEMBL8769203 | 0.85 | ACHE (0.63) | ACHETSHR | |
| SCHEMBL8833233 | 0.85 | ACHE (0.40) | HRH4HRH3ACHEMAPTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022178592-A1 | SOLID PHASE SYNTHESIS OF GLUTAMATE-UREA-LYSINE DERIVED (GUL DERIVED) PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETING CONJUGATES AND THEIR USE AS PRECURSORS FOR THERAPEUTIC AND / OR DIAGNOSTIC AGENTS | Telix International Pty Ltd (AU) | 2022-09-01 | — | — | WO | disclosed |